International Journal of Nanomedicine · 2022 · 20 citations · 24 references
The potent Drp1 agonist, rifampicin, induced OS apoptosis and exosome loading, improving OS targeting and mouse survival rates. EXO-RIF is a promising strategy for the treatment of diverse malignancies.
24
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar, Valerie S. LeBleu, Hikaru Sugimoto et al. · Nature · 2017 · 2.5K citations
New Horizons in the Treatment of Osteosarcoma
New England Journal of Medicine · 2021 · 597 citations
Rifampicin: A New Orally Active Rifamycin
N. Maggi, C.R. Pasqualucci, R Ballotta et al. · Chemotherapy · 1966 · 266 citations
Pharmaceutical Science, Pharmacotherapy, Antimicrobial Chemotherapy +17